The FDA has approved Adzynma, the first recombinant protein product for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. cTTP is caused by a mutation in the ADAMTS13 gene, resulting in a deficiency of the ADAMTS13 enzyme responsible for regulating blood clotting. Adzynma is a purified recombinant form of the enzyme that can be administered prophylactically or on-demand to reduce the risk of clotting/bleeding and treat acute events. The safety and effectiveness of Adzynma were demonstrated in a global study, and the most common side effects include headache, diarrhea, and abdominal pain. The approval of Adzynma provides a much-needed treatment option for patients with cTTP.
Researchers have discovered a link between adenovirus infections and a rare blood clotting disorder, shedding new light on the virus and its role in causing severe thrombocytopenia. This marks the first time adenovirus, a common respiratory virus that causes mild symptoms similar to the common cold and flu, has been implicated in blood clotting and anti-platelet factor 4 (PF4) disorders. The findings prompt further research on the treatment and prevalence of this life-threatening disorder and raise questions about its occurrence with adenovirus infections and other viruses.
Researchers from the University of North Carolina School of Medicine have discovered a link between adenovirus infection, which causes cold and flu-like symptoms, and a rare blood clotting disorder accompanied by severe thrombocytopenia. The study identified the virus's role in triggering an anti-platelet factor 4 disorder, providing new insights for earlier diagnosis and optimized treatment. The disorder, one of four recognized anti-PF4 disorders, leads to excessive blood clotting and a drop in platelet levels. Further research is needed to understand the prevalence of the disorder, its causes, and the most effective treatment methods.
